Read by QxMD icon Read

Schizophrenia Research

Matteo Cella, Til Wykes
BACKGROUND: Cognitive Remediation (CR) is an evidence based treatment targeting cognitive and functional difficulties in people with psychosis. Despite the large number of effectiveness studies, only limited evidence exists for the active ingredients of this therapy. This study begins to fill this gap by exploring the relationship between CR ingredients, including alliance with a therapist, and therapy outcomes. METHOD: This is a secondary analysis based on data from a published randomised controlled trial comparing CR+treatment-as-usual (TAU) to TAU alone...
September 14, 2017: Schizophrenia Research
Victor Peralta, Lourdes Fañanás, Migdyrai Martín-Reyes, Manuel J Cuesta
BACKGROUND: This study examines the familial aggregation (familiality) of different phenotypic definitions of catatonia in a sample of multiplex families with psychotic and mood disorders. METHODS: Participants were probands with a lifetime diagnosis of a DSM-IV functional psychotic disorder, their parents and at least one first-degree relative with a psychotic disorder. The study sample included 441 families comprising 2703 subjects, of whom 1094 were affected and 1609 unaffected...
September 14, 2017: Schizophrenia Research
Ole Schjerning, Per Damkier, Signe Engelhardt Lykkegaard, Klaus Damgaard Jakobsen, Jimmi Nielsen
INTRODUCTION: Anxiety is frequent in patients with schizophrenia and poses a major impact on patients perceived quality of life, daily functioning and risk of suicide. Pregabalin has shown effective in the treatment of generalized anxiety disorder and has been suggested for the treatment of anxiety in patients with schizophrenia. As evidence is sparse regarding treatment of anxiety in this patient group, we aimed to investigate the use of pregabalin for anxiety in patients with schizophrenia...
September 14, 2017: Schizophrenia Research
Irene M Hurford, Joseph Ventura, Stephen R Marder, Steven P Reise, Robert M Bilder
INTRODUCTION: Schizophrenia is marked by a global cognitive impairment that contributes significantly to chronic disability and unemployment. As new treatments are developed for cognition in schizophrenia, clinicians require easily administered instruments to assess cognition. We previously developed a very brief cognitive battery (Bell et al., 2005). The Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) was developed specifically to provide clinicians with a way to assess cognition in their patients with schizophrenia...
September 13, 2017: Schizophrenia Research
Chad A Bousman, Tae Young Lee, Minah Kim, Junhee Lee, Md Shaki Mostaid, Minji Bang, Suk Kyoon An, Ian P Everall, Christos Pantelis, Jun Soo Kwon
No abstract text is available yet for this article.
September 12, 2017: Schizophrenia Research
Jules R Dugré, Jean-Pierre Guay, Alexandre Dumais
Clinicians are often left with the difficult task of assessing and managing the risk of violent behaviors in individuals having command hallucinations, which may result in substantial rates of false positive or false negative. Moreover, findings on the association between command hallucinations and suicidal behaviors are limited. In an attempt to better understand compliance to this hallucinatory phenomenon, our objective was to identify the risk factors of compliance with self-harm command hallucinations. Secondary analyses from the MacArthur Study were performed on 82 participants with psychosis reporting such commands...
September 11, 2017: Schizophrenia Research
Yansong Liu, Shuquan Rao, Yong Xu, Fuquan Zhang, Zhiqiang Wang, Xudong Zhao
No abstract text is available yet for this article.
September 11, 2017: Schizophrenia Research
Madeleine Johansson, Fredrik Hjärthag, Lars Helldin
A decade has passed since the standardized remission criteria of schizophrenia spectrum disorders-the Andreasen Criteria-were defined. Over 2000 studies have been published, but only a few describe symptomatic remission over time. In this prospective study we followed patients for 3 and 5years, respectively. The aim was to investigate how different symptoms affect the occurrence of remission and how the remission cut-off level affects remission sustainability. The participants were patients diagnosed with schizophrenia spectrum disorders (DSM-IV)...
September 9, 2017: Schizophrenia Research
Sudhakar Selvaraj, Peter S Bloomfield, Bo Cao, Mattia Veronese, Federico Turkheimer, Oliver D Howes
Patients with schizophrenia show whole brain and cortical gray matter (GM) volume reductions which are progressive early in their illness. Microglia, the resident immune cells in the CNS, phagocytose neurons and synapses. Some post mortem and in vivo studies in schizophrenia show evidence for elevated microglial activation compared to matched controls. However, it is currently unclear how these results relate to changes in cortical structure. METHODS: Fourteen patients with schizophrenia and 14 ultra high risk for psychosis (UHR) subjects alongside two groups of age and genotype matched healthy controls received [(11)C]PBR28 PET scans to index TSPO expression, a marker of microglial activation and a 3T MRI scan...
September 8, 2017: Schizophrenia Research
Manuel J Cuesta, Elena García de Jalón, M Sol Campos, Lucía Moreno-Izco, Ruth Lorente-Omeñaca, Ana M Sánchez-Torres, Víctor Peralta
Motor abnormalities (MAs) are highly prevalent in patients with first-episode psychosis both before any exposure and after treatment with antipsychotic drugs. However, the extent to which these abnormalities have predictive value for long-term psychosocial functioning is unknown. One hundred antipsychotic-naive first-episode psychosis (FEP) patients underwent extensive motor evaluation including catatonic, parkinsonism, dyskinesia, akathisia and neurological soft signs. Patients were assessed at naïve state and 6months later...
September 7, 2017: Schizophrenia Research
G Fond, L Boyer, M Andrianarisoa, O Godin, L Brunel, E Bulzacka, N Coulon, P M Llorca, F Berna, B Aouizerate, D Capdevielle, T D'Amato, C Dubertret, J Dubreucq, C Faget, F Gabayet, J Mallet, D Misdrahi, R Rey, R Richieri, P Roux, C Passerieux, A Schandrin, A M Tronche, P Vidailhet, M Leboyer, F Schürhoff
OBJECTIVES: Reducing the duration of untreated psychosis (DUP) may improve the prognosis of schizophrenia. This study investigated the prevalence, and associated risk factors, of long DUP in a large, non-selected sample of community-dwelling schizophrenia patients (SZ). METHOD: 478 community-dwelling stable SZ participants (122 women and 356 men; mean age 32.37±9.86years) were recruited between 2010 and 2016. The mean retrospective DUP was evaluated from both patient and family reports, as well as hospital/psychiatrists records...
September 6, 2017: Schizophrenia Research
Helena P G Joaquim, Marcus V Zanetti, Mauricio H Serpa, Martinus T Van de Bilt, Paulo C Sallet, Tiffany M Chaim, Geraldo F Busatto, Wagner F Gattaz, Leda L Talib
Past studies have linked intracellular pathways related to psychotic disorders to the GSK3B enzyme. This study aimed to investigate GSK3B protein expression and phosphorylation in drug-naïve first-episode psychosis patients (n=43) at baseline and following symptom remission, and in healthy controls (n=77). At baseline GSK3B total level was higher in patients (p<0.001). In schizophrenia spectrum patients (n=25) GSK3B total and phosphorylated levels were higher than in controls and patients with other non-affective psychotic disorders (n=18) (p<0...
September 6, 2017: Schizophrenia Research
Ross M G Norman, Arlene MacDougall, Rahul Manchanda, Raj Harricharan
Recovery from psychotic disorders includes both symptomatic and functional components. Progress in understanding recovery requires careful replication and extension of findings using comparable measures. In the current paper, we present a study of five year recovery rates in an early intervention program in London, Canada with the same operational criteria as those used in a previous report from the OPUS cohort in Denmark. Our analysis extends the OPUS reports by including additional potential predictors of overall recovery, such as cognitive functioning, adherence to medication and early social support, and examining rates and predictors of individual components of recovery at five year follow-up...
September 6, 2017: Schizophrenia Research
Martien Wampers, Sofie Schrauwen, Marc De Hert, Leen Gielen, Walter Schaeken
Pragmatic language difficulties in people with psychosis have been demonstrated repeatedly but one of the most studied types of pragmatic language, i.e. scalar implicatures (SIs), has not yet been examined in this population. SIs are a special kind of pragmatic inferences, based on linguistic expressions like some, or, must. Such expressions are part of a scale of informativeness organized by informativity (e.g. some/many/all). Although semantically the less informative expressions imply the more informative ones, pragmatically people generally infer that the use of a less informative expression implies that the more informative option is not applicable...
September 6, 2017: Schizophrenia Research
Ryan Wui Hang Ho, Wing Chung Chang, Vivian Wing Yan Kwong, Emily Sin Kei Lau, Gloria Hoi Kei Chan, Olivia Tsz Ting Jim, Christy Lai Ming Hui, Sherry Kit Wa Chan, Edwin Ho Ming Lee, Eric Yu Hai Chen
BACKGROUND: Self-stigma represents a major barrier to recovery in people with psychotic disorders but is understudied in early illness stage. Longitudinal investigation of prediction for self-stigma is scarce and none is conducted in early psychosis. We aimed to prospectively examine baseline predictors of self-stigma in early psychosis patients in the context of a 3-year follow-up of a randomized-controlled trial (RCT) comparing 1-year extension of early intervention (EI) with step-down psychiatric care for first-episode psychosis (FEP)...
September 6, 2017: Schizophrenia Research
Gregory P Strauss, Ian M Raugh, Vijay A Mittal, Brandon E Gibb, Meredith E Coles
Prior studies indicate an association between psychotic-like experiences (PLEs) and bullying victimization; however, the most frequent types of bullying victimization and the association with bullying perpetration are unclear. A community sample of 1563 adolescents completed questionnaires examining PLEs and frequency of bullying victimization and perpetration. Compared to adolescents scoring below the psychosis-risk cut-off (n=1294), those with PLEs (who are putatively at-risk) (n=269) were more likely to report being the victims of overt, relational, and reputational bullying and to have perpetrated bullying against others...
September 6, 2017: Schizophrenia Research
Sanne Koops, Christina W Slotema, Claire Kos, Leonie Bais, André Aleman, Jan Dirk Blom, Iris E C Sommer
No abstract text is available yet for this article.
September 6, 2017: Schizophrenia Research
Daniela Čiháková, William W Eaton, Monica V Talor, Uasim H Harkus, Haley K Demyanovich, Katrina Rodriguez, Stephanie Feldman, Deanna L Kelly
No abstract text is available yet for this article.
September 5, 2017: Schizophrenia Research
Vicente Molina, Alejandro Bachiller, Javier Gomez-Pilar, Alba Lubeiro, Roberto Hornero, Benjamín Cea-Cañas, César Valcárcel, Mahmoun-Karim Haidar, Jesús Poza
Spectral entropy (SE) is a measurement from information theory field that provides an estimation of EEG regularity and may be useful as a summary of its spectral properties. Previous studies using small samples reported a deficit of EEG entropy modulation in schizophrenia during cognitive activity. The present study is aimed at replicating this finding in a larger sample, to explore its cognitive and clinical correlates and to discard antipsychotic treatment as the main source of that deficit. We included 64 schizophrenia patients (21 first episodes, FE) and 65 healthy controls...
September 5, 2017: Schizophrenia Research
Steffi Malik, John Lally, Olesya Ajnakina, Megan Pritchard, Amir Krivoy, Fiona Gaughran, Hitesh Shetty, Robert J Flanagan, James H MacCabe
BACKGROUND: The use of clozapine is limited due to the occurrence of neutropenia, and the rare but life threatening adverse event of agranulocytosis. There is little epidemiological research into clinical factors that may impact on this risk. We conducted a case control study examining the clinical risk factors for neutropenia patients treated with clozapine. METHOD: A case-control study was conducted within a database of anonymised electronic clinical records. All patients who discontinued clozapine due to a neutropenic event were included as cases...
September 4, 2017: Schizophrenia Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"